Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    Online & In-Person

    What is this Study about?

    The aim of this study is to assess the feasibility of the Nighttime Insomnia Treatment and Education for Canadians with Alzheimer’s Disease (NITE-CAD) program. NITE-CAD is a 6-week lifestyle intervention program aimed to improve sleep in people living with dementia by supporting their care partners. The information gathered will be used to improve the program for future offerings.

    Eligibility Criteria

    • Care partner to someone living with dementia with sleep difficulties

    • Are living with dementia experiencing sleep difficulties, with a live-in care partner who is interested in participating

    • Able to speak and understand English

    • Have access to the internet and a computer with a camera and microphone

    • Able to participate in an exercise program

    • Sufficient cognitive function to follow two-step commands.

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    This study will uncover how bilingualism supports healthy cognitive aging by examining the influence of different language experiences on the timing and location of brain network activity. We will examine the timing of brain activity using electroencephalography (EEG; i.e., recordings of electrical brain activity) and the location of brain activity using magnetic resonance imaging (MRI; i.e., images of activity in different parts of the brain). Different language experience factors will additionally be explored. By measuring multiple factors (e.g., the age of second language learning, language proficiency) the effect(s) of different language experiences on the brain and cognition will become clearer.

    Eligibility Criteria

    You are eligible to participate if you:

    - are a French-English bilingual over the age of 65

    - have mild cognitive impairment

    - have Alzheimer's disease

    - are a healthy older adult (i.e., have no cognitive conditions)

     

    Please note that you do not need to be completely fluent in both English and French, just to have some familiarity, experience or training with both languages to be eligible to participate.

    Thank you for your consideration!

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    In this study we aim to explore the motivations and impacts of disclosure a personal diagnosis of dementia or being a care partner on social media. The overall goal of the study is to develop an evidence-based resource to promote benefits of social media for the dementia community while minimizing its harms.

    Eligibility Criteria

    -Identify as an individual living with dementia

    -Identify as a care partner

    -Are over the age of 19

    -Have posted on social media about living with dementia or being a care partner

    -Speak English

    If you are interested in participating, please contact [email protected] or sign up using the following link: https://ubc.ca1.qualtrics.com/jfe/form/SV_5nGjQ2K27SEZwOi

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Early detection of brain changes is crucial to prevent cognitive decline and dementia. This study uses electroencephalography (EEG) to record the brain's electrical signals during simple tasks, with the hope of validating a measure that can improve early detection of Alzheimer’s disease.

    We are recruiting 150 individuals with mild memory issues and mild dementia at Baycrest in Toronto and Bruyère in Ottawa. In a separate study we are also recruiting older adults with no memory problems. The results of both studies together will help us determine if our new EEG measure can detect abnormal changes in brain health early on and if it can help predict future cognitive changes. We hope that this new test will be used in the clinic to identify individuals who may benefit the most from early treatment and interventions.

    Eligibility Criteria

    - Are between 60 and 85 years of age

    - Have a diagnosis of amnestic mild cognitive impairment or mild dementia due to Alzheimer’s

    - Have normal vision (with visual aids, if needed) and no other serious health issues

    - Ability to speak English

    Recruitment End Date

  • Observational Study
    Online & In-Person

    What is this Study about?

    A dementia diagnosis impacts the cognitive, functional, and physical abilities of those diagnosed, which will influence their ability to perform activities of daily living including meal preparation and eating. Persons living with dementia can experience a range of difficulties while eating that will impact their ability to consume adequate food and fluids, which include but are not limited to swallowing, chewing, and self-feeding difficulties. Consequently, persons living with dementia are at increased risk of malnutrition and negative health outcomes. The objective of this study is to understand the experience of persons’ living with dementia or diagnosed memory problems and/or their caregivers in managing eating challenges and swallowing problems in the community.

    Eligibility Criteria

    You are eligible to participate if you:
    - Speak English
    - A person with memory problems experiencing eating challenges or swallowing problems in the community
    - OR if you are or were a caregiver to a person with memory problems with eating challenges or swallowing problems.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.

    Eligibility Criteria

    60+
    Diagnosis of Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

    Eligibility Criteria

    You are eligible to participate if you meet the following criteria:

    • Age ≥ 55; females must be post-menopausal

    • DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)

    • sMMSE ≤ 24

    • Clinically significant agitation based on IPA definition

    • Stable cognition-enhancing medication for at least 3 months prior to study enrolment

    • Availability of a caregiver to accompany participant to study visits and to participate in the study

    • Ability to speak English

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    The study is aiming to assess whether nutritional intervention with personalized, preselected prebiotics can affect cognitive function in those with Alzheimer’s disease. This study is placebo-controlled, and participants will be randomized to either the placebo or prebiotic.

    Eligibility Criteria

    • Aged 60 or older
    • Diagnosis of Mild Cognitive Impairment, Alzheimer’s disease, or Amnestic Mild Cognitive Impairment
    • Has someone who can be their study partner

    Recruitment End Date